Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit

Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit 

Oxford and London, UK – 09 June 2021. Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) and Dark Antigen™ discovery platforms to deliver targeted cancer immunotherapies, will present at the 2^nd TCR-based Therapies Summit on 9 June.

At this event, Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present a talk entitled “Overcoming Challenges of Classical TCR Targets with Novel, MR1 Cancer-Specific TCRs.”

MR1 is an unconventional HLA-like target that appears to present cancer-specific, metabolite ligands to the immune system. Enara Bio are developing TCRs that target MR1 and selectively kill multiple different human cancer types while remaining inert to non-cancerous cells (Crowther, M.D., et al. Nat Immunol (2020) doi:10.1038/s41590-019-0578-8).

In her presentation, Dr. Abbott will provide an overview of the advances and potential benefits of TCR-based therapies, together with the challenges associated with traditional TCR targets. She will introduce MR1 as a novel target and outline the potential of MR1-restricted TCR-T cells to treat a broad range of cancer patients independent of tumor type and HLA-type. Dr. Abbott will also present early pre-clinical data for Enara Bio’s lead autologous MR1-targeted TCR-T cell therapy ENA-0001, which the Company is advancing to first in human trials.

The presentation will take place on 9 June at 09:30 EST. For more details, please visit

TCR-based Therapies Summit 2021 – Solid Tumor T Cell Therapy (tcr-therapies-summit.com)